Early detection & diagnosis of Alzheimer’s disease


Learn More

About Us

Read more about Brainsymphonics & our company history & leadership.

Our Science

Our EBPS-AD software is based on a decade of AD research progress.


Access links to Alzheimer’s disease research & other online resources.

Latest News

October 2019 - Biogen will seek federal approval for new Alzheimer’s drug

Biogen, based in Cambridge, Massachusetts, announced on 22 October that it would seek approval from the US Food and Drug Administration for its drug aducanumab to treat early-stage Alzheimer’s disease, for which there is currently no available treatment.

January 2019 - Brainsymphonics EBPS-AD software accepted for review by FDA

Brainsymphonics EBPS-AD software De Novo application is accepted by FDA in Jan 2019 and now it is pending approval.

Shi-Jiang Li, PhD & Piero Antuono, MD received the 2018 Dean's Award in Clinical & Translational Research

Shi-Jiang Li, PhD (professor of biophysics), and Piero Antuono, MD (professor of neurology, pharmacology, and toxicology), received the 2018 Dean’s Award in Clinical & Translational Research for their contribution to advancing translational science to improve patient health with their Alzheimer’s disease research.

Dr. Shi-Jiang Li, recipient of the 2017 Alzheimers Award from JAD

Dr. Shi-Jiang Li has been chosen as the recipient of the 2017 Alzheimers Award from the Journal of Alzheimer’s Disease (JAD).

Our Mission

At Brainsymphonics, our mission is to provide early detection and diagnosis of Alzheimer’s disease (AD) using resting-state fMRI approach.

Our EBPS-AD software application quantitatively and accurately assesses the stage of AD in individuals, and enables timely and cost-effective intervention, thus enhancing patients’ quality of life and reducing AD’s overwhelming societal cost.


16600 W National Avenue
New Berlin, WI 53151

Quick Contact Form

1 + 15 =